{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:27:47Z","timestamp":1790645267162,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00277-024-05920-8","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T05:03:14Z","timestamp":1723006994000},"page":"3287-3291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Myeloproliferative neoplasms: young patients, current data and future considerations"],"prefix":"10.1007","volume":"103","author":[{"given":"Marta","family":"Sobas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Ianotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Kiladjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"issue":"11","key":"5920_CR1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP et al (2022) International Consensus classification of myeloid neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 140(11):1200\u20131228","journal-title":"Blood"},{"issue":"1","key":"5920_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00277-017-3165-9","volume":"97","author":"P Boddu","year":"2018","unstructured":"Boddu P, Masarova L, Verstovsek S et al (2018) Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Ann Hematol 97(1):109\u2013121","journal-title":"Ann Hematol"},{"issue":"12","key":"5920_CR3","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1002\/ajh.25270","volume":"93","author":"N Szuber","year":"2018","unstructured":"Szuber N, Vallapureddy RR, Penna D et al (2018) Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. Am J Hematol 93(12):1474\u20131484","journal-title":"Am J Hematol"},{"issue":"6","key":"5920_CR4","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/ejh.13232","volume":"102","author":"M Barzilai","year":"2019","unstructured":"Barzilai M, Kirgner I, Avivi I et al (2019) Characteristics and outcomes of young adults with Philadelphia-negative myeloproliferative neoplasms. Eur J Haematol 102(6):504\u2013508","journal-title":"Eur J Haematol"},{"issue":"1","key":"5920_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s00277-023-05564-0","volume":"103","author":"NP Horvat","year":"2024","unstructured":"Horvat NP, Abdallah EF, Xie Z et al (2024) Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities. Ann Hematol 103(1):117\u2013123","journal-title":"Ann Hematol"},{"issue":"3","key":"5920_CR6","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/bjh.18650","volume":"201","author":"Z Harris","year":"2023","unstructured":"Harris Z, Kaizer H, Wei A et al (2023) Characterization of myeloproliferative neoplasms in the paediatric and young adult population. Br J Haematol 201(3):449\u2013458","journal-title":"Br J Haematol"},{"issue":"17","key":"5920_CR7","doi-asserted-by":"publisher","first-page":"5171","DOI":"10.1182\/bloodadvances.2022007201","volume":"6","author":"M Sobas","year":"2022","unstructured":"Sobas M, Kiladjian JJ, Beauverd Y et al (2022) Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs. Blood Adv 6(17):5171\u20135183","journal-title":"Blood Adv"},{"issue":"3","key":"5920_CR8","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s41375-024-02155-4","volume":"38","author":"JT England","year":"2024","unstructured":"England JT, Szuber N, Sirhan S et al (2024) Clinical features and long-term outcomes of a pan-canadian cohort of adolescents and young adults with myeloproliferative neoplasms: a Canadian MPN Group Study. Leukemia 38(3):570\u2013578","journal-title":"Leukemia"},{"issue":"12","key":"5920_CR9","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1038\/leu.2015.205","volume":"29","author":"A Karow","year":"2015","unstructured":"Karow A, Nienhold R, Lundberg P et al (2015) Mutational profile of childhood myeloproliferative neoplasms. Leukemia 29(12):2407\u20132409","journal-title":"Leukemia"},{"issue":"6","key":"5920_CR10","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1038\/s41375-018-0349-9","volume":"33","author":"JS Fowles","year":"2019","unstructured":"Fowles JS, How J, Allen MJ et al (2019) Young versus old age at diagnosis confers distinct genomic profiles in patients with polycythemia vera. Leukemia 33(6):1522\u20131526","journal-title":"Leukemia"},{"key":"5920_CR11","doi-asserted-by":"crossref","unstructured":"Cordua S, Kjaer L, Skov V et al Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population. Blood. 20191;134(5):469\u2013479","DOI":"10.1182\/blood.2019001113"},{"issue":"3","key":"5920_CR12","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.rdc.2020.03.001","volume":"46","author":"DI Bekele","year":"2020","unstructured":"Bekele DI, Patnaik MM, Autoimmunity (2020) Clonal hematopoiesis, and Myeloid Neoplasms. Rheum Dis Clin North Am 46(3):429\u2013444","journal-title":"Rheum Dis Clin North Am"},{"issue":"2","key":"5920_CR13","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.leukres.2012.10.020","volume":"37","author":"HC Hasselbalch","year":"2013","unstructured":"Hasselbalch HC (2013) Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leuk Res 37(2):214\u2013220","journal-title":"Leuk Res"},{"issue":"2","key":"5920_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11899-020-00571-8","volume":"15","author":"N Kucine","year":"2020","unstructured":"Kucine N (2020) Myeloproliferative neoplasms in children, adolescents, and young adults. Curr Hematol Malig Rep 15(2):141\u2013148","journal-title":"Curr Hematol Malig Rep"},{"issue":"3","key":"5920_CR15","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1055\/s-0034-1370794","volume":"40","author":"A Falanga","year":"2014","unstructured":"Falanga A, Marchetti M (2014) Thrombosis in myeloproliferative neoplasms. Semin Thromb Hemost 40(3):348\u2013358","journal-title":"Semin Thromb Hemost"},{"issue":"13","key":"5920_CR16","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","volume":"122","author":"T Barbui","year":"2013","unstructured":"Barbui T, Finazzi G, Falanga A (2013) Myeloproliferative neoplasms and thrombosis. Blood 122(13):2176\u20132184","journal-title":"Blood"},{"issue":"26","key":"5920_CR17","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T, Finazzi G, Carobbio A et al (2012) Development and validation of an International Prognostic score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 120(26):5128\u20135133","journal-title":"Blood"},{"issue":"4","key":"5920_CR18","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/ajh.24293","volume":"91","author":"M Haider","year":"2016","unstructured":"Haider M, Gangat N, Lasho T et al (2016) Validation of the revised International Prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients. Am J Hematol 91(4):390\u2013394","journal-title":"Am J Hematol"},{"issue":"4","key":"5920_CR19","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1016\/S2352-3026(22)00046-1","volume":"9","author":"M Marchetti","year":"2022","unstructured":"Marchetti M, Vannucchi AM, Griesshammer M et al (2022) Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol 9(4):e301\u2013e311","journal-title":"Lancet Haematol"},{"issue":"2","key":"5920_CR20","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41375-023-02114-5","volume":"38","author":"H Pasquer","year":"2024","unstructured":"Pasquer H, Daltro de Oliveira R, Vasseur L et al (2024) Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification. Leukemia 38(2):326\u2013339","journal-title":"Leukemia"},{"key":"5920_CR21","doi-asserted-by":"publisher","first-page":"107420","DOI":"10.1016\/j.leukres.2023.107420","volume":"136","author":"C Pescia","year":"2024","unstructured":"Pescia C, Lopez G, Cattaneo D et al (2024) The molecular landscape of myeloproliferative neoplasms associated with splanchnic vein thrombosis: current perspective. Leuk Res 136:107420","journal-title":"Leuk Res"},{"issue":"5","key":"5920_CR22","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/ajh.26896","volume":"98","author":"JJ Kiladjian","year":"2023","unstructured":"Kiladjian JJ, Cassinat B (2023) Myeloproliferative neoplasms and splanchnic vein thrombosis: contemporary diagnostic and therapeutic strategies. Am J Hematol 98(5):794\u2013800","journal-title":"Am J Hematol"},{"issue":"3","key":"5920_CR23","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","volume":"7","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P, PROUD-PV Study Group et al (2020) Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol 7(3):e196\u2013e208","journal-title":"Lancet Haematol"},{"issue":"5","key":"5920_CR24","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","volume":"36","author":"JJ Kiladjian","year":"2022","unstructured":"Kiladjian JJ, Klade C, Georgiev P, PROUD-PV Study Group et al (2022) Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b. Leukemia 36(5):1408\u20131411","journal-title":"Leukemia"},{"issue":"3","key":"5920_CR25","doi-asserted-by":"publisher","first-page":"342354","DOI":"10.1007\/s12185-021-03171-1","volume":"114","author":"W Gu","year":"2021","unstructured":"Gu W, Yang R, Xiao Z et al (2021) Clinical outcomes of interferon therapy for polycythemia vera and essential thrombocythemia: a systematic review and meta-analysis. Int J Hematol 114(3):342354","journal-title":"Int J Hematol"},{"issue":"7","key":"5920_CR26","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1007\/s00277-024-05665-4","volume":"103","author":"JJ Kiladjian","year":"2024","unstructured":"Kiladjian JJ, Marin FF, Al-Ali HK et al (2024) ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options. Ann Hematol 103(7):2299\u20132310","journal-title":"Ann Hematol"},{"issue":"19","key":"5920_CR27","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1182\/blood.2021012743","volume":"139","author":"J Mascarenhas","year":"2022","unstructured":"Mascarenhas J, Kosiorek HE, Prchal JT et al (2022) A randomized phase 3 trial of interferon-\u03b1 vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood 139(19):2931\u20132941","journal-title":"Blood"},{"key":"5920_CR28","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3324\/haematol.2017.181297","volume":"103","author":"J-C Ianotto","year":"2017","unstructured":"Ianotto J-C, Chauveau A, Boyer-Perrard F et al (2017) Benefits and pitfalls of pegylated interferon-\u03b12a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study. Haematologica 103:438\u2013446","journal-title":"Haematologica"},{"issue":"7","key":"5920_CR29","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.3390\/cancers12071954","volume":"12","author":"J How","year":"2020","unstructured":"How J, Hobbs G (2020) Use of Interferon Alfa in the treatment of Myeloproliferative neoplasms: perspectives and review of the literature. Cancers (Basel) 12(7):1954","journal-title":"Cancers (Basel)"},{"issue":"Supplement 1","key":"5920_CR30","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1182\/blood-2023-185108","volume":"142","author":"Y Beauverd","year":"2023","unstructured":"Beauverd Y, Ianotto JC, Thaw KH, Sobas M, Sadjadian P, Curto-Garcia N et al (2023) Impact of cytoreductive drugs upon outcomes in a contemporary cohort of adolescent and young adults with essential thrombocythemia and Polycythemia Vera. Blood 142(Supplement 1):748\u2013748","journal-title":"Blood"},{"issue":"24","key":"5920_CR31","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1182\/blood-2015-07-659060","volume":"126","author":"E Verger","year":"2015","unstructured":"Verger E, Cassinat B, Chauveau A et al (2015) Clinical and molecular response to interferon-\u03b1 therapy in essential thrombocythemia patients with CALR mutations. Blood 126(24):2585\u20132591","journal-title":"Blood"},{"issue":"22","key":"5920_CR32","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1182\/blood.2021010986","volume":"138","author":"M Mosca","year":"2021","unstructured":"Mosca M, Hermange G, Tisserand A et al (2021) Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFN\u03b1 in myeloproliferative neoplasms. Blood 138(22):2231\u20132243","journal-title":"Blood"},{"issue":"14","key":"5920_CR33","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1002\/cncr.30679","volume":"123","author":"RT Silver","year":"2017","unstructured":"Silver RT, Barel AC, Lascu E et al (2017) The effect of initial molecular profile on response to recombinant interferon-\u03b1 (rIFN\u03b1) treatment in early myelofibrosis. Cancer 123(14):2680\u20132687","journal-title":"Cancer"},{"key":"5920_CR34","first-page":"1","volume":"57","author":"CU Rank","year":"2015","unstructured":"Rank CU, Bjerrum OW, Larsen TS et al (2015) Minimal residual disease after long-term Interferon-Alpha2 treatment. A Report on Hematological, Molecular, and histomorphological response patterns in ten patients with essential thrombocythemia and Polycythemia Vera. Leuk Lymphoma 57:1\u201326","journal-title":"Leuk Lymphoma"},{"key":"5920_CR35","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1055\/s-2006-942762","volume":"32","author":"J-J Kiladjian","year":"2006","unstructured":"Kiladjian J-J, Rain J-D, Bernard J-F et al (2006) Long-term incidence of hematological evolution in three French prospective studies of Hydroxyurea and Pipobroman in Polycythemia Vera and essential thrombocythemia. Semin Thromb Hemost 32:417\u2013421","journal-title":"Semin Thromb Hemost"},{"key":"5920_CR36","doi-asserted-by":"crossref","unstructured":"Landtblom AR, Andersson TM, Johansson ALV Pregnancy and childbirth outcomes in women with myeloproliferative neoplasms-a nationwide population-based study of 342 pregnancies in Sweden. Leukemia. ;36(10):2461\u20132467. Robinson S, Ragheb M, Harrison C et al (2022)","DOI":"10.1038\/s41375-022-01688-w"},{"issue":"9","key":"5920_CR37","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1182\/blood.2023020729","volume":"143","author":"I How","year":"2024","unstructured":"How I (2024) Treat myeloproliferative neoplasms in pregnancy. Blood 143(9):777\u2013785","journal-title":"Blood"},{"issue":"4","key":"5920_CR38","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s11899-019-00527-7","volume":"14","author":"L Masarova","year":"2019","unstructured":"Masarova L, Bose P, Verstovsek S (2019) The Rationale for Immunotherapy in Myeloproliferative Neoplasms. Curr Hematol Malig Rep 14(4):310\u2013327","journal-title":"Curr Hematol Malig Rep"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05920-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05920-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05920-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T09:19:18Z","timestamp":1724836758000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05920-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["5920"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05920-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,7]]},"assertion":[{"value":"23 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}